These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 38513684)

  • 21. Safety and immunogenicity of Pfs25H-EPA/Alhydrogel, a transmission-blocking vaccine against Plasmodium falciparum: a randomised, double-blind, comparator-controlled, dose-escalation study in healthy Malian adults.
    Sagara I; Healy SA; Assadou MH; Gabriel EE; Kone M; Sissoko K; Tembine I; Guindo MA; Doucoure M; Niaré K; Dolo A; Rausch KM; Narum DL; Jones DL; MacDonald NJ; Zhu D; Mohan R; Muratova O; Baber I; Coulibaly MB; Fay MP; Anderson C; Wu Y; Traore SF; Doumbo OK; Duffy PE
    Lancet Infect Dis; 2018 Sep; 18(9):969-982. PubMed ID: 30061051
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials.
    Yang S; Li Y; Dai L; Wang J; He P; Li C; Fang X; Wang C; Zhao X; Huang E; Wu C; Zhong Z; Wang F; Duan X; Tian S; Wu L; Liu Y; Luo Y; Chen Z; Li F; Li J; Yu X; Ren H; Liu L; Meng S; Yan J; Hu Z; Gao L; Gao GF
    Lancet Infect Dis; 2021 Aug; 21(8):1107-1119. PubMed ID: 33773111
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial.
    Ishola D; Manno D; Afolabi MO; Keshinro B; Bockstal V; Rogers B; Owusu-Kyei K; Serry-Bangura A; Swaray I; Lowe B; Kowuor D; Baiden F; Mooney T; Smout E; Köhn B; Otieno GT; Jusu M; Foster J; Samai M; Deen GF; Larson H; Lees S; Goldstein N; Gallagher KE; Gaddah A; Heerwegh D; Callendret B; Luhn K; Robinson C; Leyssen M; Greenwood B; Douoguih M; Leigh B; Watson-Jones D;
    Lancet Infect Dis; 2022 Jan; 22(1):97-109. PubMed ID: 34529963
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Blood-stage malaria vaccine candidate RH5.1/Matrix-M in healthy Tanzanian adults and children; an open-label, non-randomised, first-in-human, single-centre, phase 1b trial.
    Silk SE; Kalinga WF; Salkeld J; Mtaka IM; Ahmed S; Milando F; Diouf A; Bundi CK; Balige N; Hassan O; Mkindi CG; Rwezaula S; Athumani T; Mswata S; Lilolime NS; Simon B; Msami H; Mohamed M; David DM; Mohammed L; Nyaulingo G; Mwalimu B; Juma O; Mwamlima TG; Sasamalo IA; Mkumbange RP; Kamage JJ; Barrett JR; King LDW; Hou MM; Pulido D; Carnrot C; Lawrie AM; Cowan RE; Nugent FL; Roberts R; Cho JS; Long CA; Nielsen CM; Miura K; Draper SJ; Olotu AI; Minassian AM
    Lancet Infect Dis; 2024 Oct; 24(10):1105-1117. PubMed ID: 38880111
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Advances in neglected tropical disease vaccines: Developing relative potency and functional assays for the Na-GST-1/Alhydrogel hookworm vaccine.
    Brelsford JB; Plieskatt JL; Yakovleva A; Jariwala A; Keegan BP; Peng J; Xia P; Li G; Campbell D; Periago MV; Correa-Oliveira R; Bottazzi ME; Hotez PJ; Diemert D; Bethony JM
    PLoS Negl Trop Dis; 2017 Feb; 11(2):e0005385. PubMed ID: 28192438
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and immunogenicity of a purified inactivated Zika virus vaccine candidate in adults primed with a Japanese encephalitis virus or yellow fever virus vaccine in the USA: a phase 1, randomised, double-blind, placebo-controlled clinical trial.
    Koren MA; Lin L; Eckels KH; De La Barrera R; Dussupt V; Donofrio G; Sondergaard EL; Mills KT; Robb ML; Lee C; Adedeji O; Keiser PB; Curley JM; Copeland NK; Crowell TA; Hutter JN; Hamer MJ; Valencia-Ruiz A; Darden J; Peel S; Amare MF; Mebrahtu T; Costanzo M; Krebs SJ; Gromowski GD; Jarman RG; Thomas SJ; Michael NL; Modjarrad K
    Lancet Infect Dis; 2023 Oct; 23(10):1175-1185. PubMed ID: 37390836
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial.
    Mallory RM; Formica N; Pfeiffer S; Wilkinson B; Marcheschi A; Albert G; McFall H; Robinson M; Plested JS; Zhu M; Cloney-Clark S; Zhou B; Chau G; Robertson A; Maciejewski S; Hammond HL; Baracco L; Logue J; Frieman MB; Smith G; Patel N; Glenn GM;
    Lancet Infect Dis; 2022 Nov; 22(11):1565-1576. PubMed ID: 35963274
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunogenicity and safety of a novel ten-valent pneumococcal conjugate vaccine in healthy infants in The Gambia: a phase 3, randomised, double-blind, non-inferiority trial.
    Clarke E; Bashorun A; Adigweme I; Badjie Hydara M; Umesi A; Futa A; Ochoge M; Obayemi D; Edem B; Saidy-Jah E; Onwuchekwa C; Dhere R; Sethna V; Kampmann B; Goldblatt D; Taylor D; Andi-Lolo I; Hosken N; Antony K; Innis BL; Alderson MR; Lamola S
    Lancet Infect Dis; 2021 Jun; 21(6):834-846. PubMed ID: 33516293
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a study.
    Baden LR; Stieh DJ; Sarnecki M; Walsh SR; Tomaras GD; Kublin JG; McElrath MJ; Alter G; Ferrari G; Montefiori D; Mann P; Nijs S; Callewaert K; Goepfert P; Edupuganti S; Karita E; Langedijk JP; Wegmann F; Corey L; Pau MG; Barouch DH; Schuitemaker H; Tomaka F;
    Lancet HIV; 2020 Oct; 7(10):e688-e698. PubMed ID: 33010242
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and immunogenicity of a novel hexavalent group B streptococcus conjugate vaccine in healthy, non-pregnant adults: a phase 1/2, randomised, placebo-controlled, observer-blinded, dose-escalation trial.
    Absalon J; Segall N; Block SL; Center KJ; Scully IL; Giardina PC; Peterson J; Watson WJ; Gruber WC; Jansen KU; Peng Y; Munson S; Pavliakova D; Scott DA; Anderson AS
    Lancet Infect Dis; 2021 Feb; 21(2):263-274. PubMed ID: 32891191
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trial.
    Afolabi MO; Ishola D; Manno D; Keshinro B; Bockstal V; Rogers B; Owusu-Kyei K; Serry-Bangura A; Swaray I; Lowe B; Kowuor D; Baiden F; Mooney T; Smout E; Köhn B; Otieno GT; Jusu M; Foster J; Samai M; Deen GF; Larson H; Lees S; Goldstein N; Gallagher KE; Gaddah A; Heerwegh D; Callendret B; Luhn K; Robinson C; Greenwood B; Leyssen M; Douoguih M; Leigh B; Watson-Jones D;
    Lancet Infect Dis; 2022 Jan; 22(1):110-122. PubMed ID: 34529962
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunogenicity and safety of a pentavalent meningococcal ABCWY vaccine in adolescents and young adults: an observer-blind, active-controlled, randomised trial.
    Peterson J; Drazan D; Czajka H; Maguire J; Pregaldien JL; Seppa I; Maansson R; O'Neill R; Balmer P; Jodar L; Jansen KU; Anderson AS; Perez JL; Beeslaar J
    Lancet Infect Dis; 2023 Dec; 23(12):1370-1382. PubMed ID: 37579773
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial.
    Ella R; Reddy S; Jogdand H; Sarangi V; Ganneru B; Prasad S; Das D; Raju D; Praturi U; Sapkal G; Yadav P; Reddy P; Verma S; Singh C; Redkar SV; Gillurkar CS; Kushwaha JS; Mohapatra S; Bhate A; Rai S; Panda S; Abraham P; Gupta N; Ella K; Bhargava B; Vadrevu KM
    Lancet Infect Dis; 2021 Jul; 21(7):950-961. PubMed ID: 33705727
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and immunogenicity of a protein subunit COVID-19 vaccine (ZF2001) in healthy children and adolescents aged 3-17 years in China: a randomised, double-blind, placebo-controlled, phase 1 trial and an open-label, non-randomised, non-inferiority, phase 2 trial.
    Gao L; Li Y; He P; Chen Z; Yang H; Li F; Zhang S; Wang D; Wang G; Yang S; Gong L; Ding F; Ling M; Wang X; Ci L; Dai L; Gao GF; Huang T; Hu Z; Ying Z; Sun J; Zuo X
    Lancet Child Adolesc Health; 2023 Apr; 7(4):269-279. PubMed ID: 36803632
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and immunogenicity of a purified inactivated Zika virus vaccine candidate in healthy adults: an observer-blind, randomised, phase 1 trial.
    Han HH; Diaz C; Acosta CJ; Liu M; Borkowski A
    Lancet Infect Dis; 2021 Sep; 21(9):1282-1292. PubMed ID: 34019802
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A randomized, controlled Phase 1b trial of the Sm-TSP-2 Vaccine for intestinal schistosomiasis in healthy Brazilian adults living in an endemic area.
    Diemert DJ; Correa-Oliveira R; Fraga CG; Talles F; Silva MR; Patel SM; Galbiati S; Kennedy JK; Lundeen JS; Gazzinelli MF; Li G; Hoeweler L; Deye GA; Bottazzi ME; Hotez PJ; El Sahly HM; Keitel WA; Bethony J; Atmar RL
    PLoS Negl Trop Dis; 2023 Mar; 17(3):e0011236. PubMed ID: 36996185
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular cloning, biochemical characterization, and partial protective immunity of the heme-binding glutathione S-transferases from the human hookworm Necator americanus.
    Zhan B; Perally S; Brophy PM; Xue J; Goud G; Liu S; Deumic V; de Oliveira LM; Bethony J; Bottazzi ME; Jiang D; Gillespie P; Xiao SH; Gupta R; Loukas A; Ranjit N; Lustigman S; Oksov Y; Hotez P
    Infect Immun; 2010 Apr; 78(4):1552-63. PubMed ID: 20145100
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An enzymatically inactivated hemoglobinase from Necator americanus induces neutralizing antibodies against multiple hookworm species and protects dogs against heterologous hookworm infection.
    Pearson MS; Bethony JM; Pickering DA; de Oliveira LM; Jariwala A; Santiago H; Miles AP; Zhan B; Jiang D; Ranjit N; Mulvenna J; Tribolet L; Plieskatt J; Smith T; Bottazzi ME; Jones K; Keegan B; Hotez PJ; Loukas A
    FASEB J; 2009 Sep; 23(9):3007-19. PubMed ID: 19380510
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and immunogenicity of a Zika purified inactivated virus vaccine given via standard, accelerated, or shortened schedules: a single-centre, double-blind, sequential-group, randomised, placebo-controlled, phase 1 trial.
    Stephenson KE; Tan CS; Walsh SR; Hale A; Ansel JL; Kanjilal DG; Jaegle K; Peter L; Borducchi EN; Nkolola JP; Makoni T; Fogel R; Bradshaw C; Tyler A; Moseley E; Chandrashekar A; Yanosick KE; Seaman MS; Eckels KH; De La Barrera RA; Thompson J; Dawson P; Thomas SJ; Michael NL; Modjarrad K; Barouch DH
    Lancet Infect Dis; 2020 Sep; 20(9):1061-1070. PubMed ID: 32618279
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Generalized urticaria induced by the Na-ASP-2 hookworm vaccine: implications for the development of vaccines against helminths.
    Diemert DJ; Pinto AG; Freire J; Jariwala A; Santiago H; Hamilton RG; Periago MV; Loukas A; Tribolet L; Mulvenna J; Correa-Oliveira R; Hotez PJ; Bethony JM
    J Allergy Clin Immunol; 2012 Jul; 130(1):169-76.e6. PubMed ID: 22633322
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.